REAL-WORLD DATA ON THE COMPARISON OF LDL-C LOWERING EFFECTS BETWEEN ALIROCUMAB AND EVOLOCUMAB

被引：0
|
作者：
Lin, D. -Y. [1 ]
Tsai, C. -L. [1 ]
Chuang, J. -Y. [2 ]
Liang, C. -H. [2 ]
Chen, Y. -H. [3 ]
Chang, Y. -H. [4 ]
Yeh, H. -I. [1 ]
Lin, C. -F. [5 ,6 ]
机构：
[1] MacKay Mem Hosp, Dept Cardiol, Taipei, Taiwan
[2] MacKay Mem Hosp, Dept Med Educ, Taipei, Taiwan
[3] Taipei Med Univ, Coll Publ Hlth, Sch Publ Hlth, Taipei, Taiwan
[4] MacKay Mem Hosp, Dept Pharm, Taipei, Taiwan
[5] MacKay Mem Hosp, Dept Cardiol, Taipei, Taiwan
[6] MacKay Med Coll, Dept Med, New Taipei, Taiwan
来源：
ATHEROSCLEROSIS | 2022年 / 355卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EP628
引用
收藏
页码：E300 / E300
页数：1
相关论文
共 50 条
  • [21] IMPORTANCE OF BASELINE LDL-C IN THE ASSOCIATION BETWEEN LDL-C LOWERING AND CARDIOVASCULAR RISK: A META-REGRESSION ANALYSIS
    Hawe, E.
    Meleth, S.
    Wolowacz, S.
    Bilitou, A.
    ATHEROSCLEROSIS, 2022, 355 : E266 - E267
  • [22] Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China
    Yuansheng Wan
    Jinyu Liu
    Xiaolian Zhan
    Yu Zhang
    Ruxu You
    Cost Effectiveness and Resource Allocation, 21
  • [23] Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China
    Wan, Yuansheng
    Liu, Jinyu
    Zhan, Xiaolian
    Zhang, Yu
    You, Ruxu
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [24] Low-density lipoprotein cholesterol lowering in real-world patients treated with evolocumab
    Desai, Nihar R.
    Wade, Rolin L.
    Xiang, Pin
    Pinto, Lionel
    Nunna, Sasikiran
    Wang, Xin
    Exter, Jason
    Mues, Katherine E.
    Habib, Mohdhar
    Chen, Chi-Chang
    CLINICAL CARDIOLOGY, 2021, 44 (05) : 715 - 722
  • [25] PHARMACODYNAMIC RELATIONSHIP BETWEEN PCSK9, ALIROCUMAB, AND LDL-C LOWERING IN FOUR PHASE 3 ODYSSEY TRIALS WITH/WITHOUT STATIN BACKGROUND
    Robinson, J. G.
    Farnier, M.
    Kastelein, J. J.
    Roth, E. M.
    Taskinen, M. R.
    Colhoun, H. M.
    Brunet, A.
    DiCioccio, A. T.
    Lecorps, G.
    Pordy, R.
    Baccara-Dinet, M. T.
    Cannon, C. P.
    ATHEROSCLEROSIS, 2016, 252 : E231 - E231
  • [26] Adverse Reactions to Evolocumab: Analysis of Real-World Data from EudraVigilance
    Calapai, Fabrizio
    Mannucci, Carmen
    Curro, Mariaconcetta
    Cardia, Luigi
    Esposito, Emanuela
    Calapai, Gioacchino
    Ammendolia, Ilaria
    PHARMACEUTICALS, 2024, 17 (03)
  • [27] EVOLOCUMAB USE AND LDL-C LOWERING IN A COHORT OF EUROPEAN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (FH) - RESULTS FROM THE HEYMANS STUDY
    Sibartie, M.
    Dhalwani, N.
    Bridges, I.
    Ebenbichler, C.
    Filardi, P. Peronne
    Vogt, A.
    Bruckert, E.
    ATHEROSCLEROSIS, 2021, 331 : E253 - E253
  • [28] The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia
    Luo, Zhu
    Huang, Zhijun
    Sun, Feng
    Guo, Fang
    Wang, Yingying
    Kao, Sheena
    Yang, Guoping
    Huang, Jie
    Li, Jiaxin
    Zhao, Sylvia
    He, YanLing
    JOURNAL OF CLINICAL LIPIDOLOGY, 2023, 17 (03) : 392 - 400
  • [29] EVOLOCUMAB USE AND LDL-C LOWERING IN A COHORT OF EUROPEAN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (FH) - RESULTS FROM THE HEYMANS STUDY
    Sibartie, M.
    Dhalwani, N.
    Ebenbichler, C.
    Filardi, P. Perrone
    Bruckert, E.
    ATHEROSCLEROSIS, 2021, 331 : E21 - E21
  • [30] LOG LINEAR ASSOCIATION BETWEEN LDL-C LOWERING AND CARDIOVASCULAR RISK REDUCTION
    Jayanna, Manju Bengaluru
    Robinson, Jennifer
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 232 - 232
12345